Jansen E N, Meerwaldt J D, Heersema T, van Manen J, Speelman J D
Department of Neurology of Ziekenhuis Ziekenzorg, Enschede, The Netherlands.
Eur Neurol. 1987;27 Suppl 1:88-92. doi: 10.1159/000116199.
In 23 patients with idiopathic Parkinson's disease presenting with severe fluctuations in motor performance and 'on-off' phenomena after long-term treatment with levodopa, the standard form of Madopar was replaced by the controlled-release form Madopar HBS. The Meerwaldt's patient card has been used to evaluate the frequency and intensity of response swings. Only 2 patients, who suffered from clear-cut 'end-of-dose' deterioration, significantly benefited by this switch from standard Madopar to Madopar HBS. Eight patients had a minimal or not essential improvement of the parkinsonian symptomatology and/or of the response fluctuations. Thirteen patients returned to their previous standard Madopar treatment after deterioration of parkinsonian symptoms or increase of dyskinesia under the HBS treatment. The overall increase in dosage of levodopa with Madopar HBS was 54% in comparison with the initial standard Madopar dosage.
在23例长期使用左旋多巴治疗后出现运动表现严重波动和“开-关”现象的特发性帕金森病患者中，将标准剂型的美多芭替换为控释剂型的美多芭HBS。使用梅尔瓦尔德特患者卡片评估反应波动的频率和强度。只有2例患有明确的“剂末”恶化的患者，从标准美多芭转换为美多芭HBS后显著受益。8例患者的帕金森症状和/或反应波动有轻微改善或无实质性改善。13例患者在接受HBS治疗后帕金森症状恶化或运动障碍加重，随后恢复使用之前的标准美多芭治疗。与初始标准美多芭剂量相比，美多芭HBS使左旋多巴的总体剂量增加了54%。
